

Tamtuvetmab

Cat. No.:	HY-P99579
CAS No.:	1608122-71-9
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tamtuvetmab (AT-005) is a caninised blontuvmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary ^{[1][2]} .								
IC ₅₀ & Target	CD52 ^[1]								
In Vivo	<p>Tamtuvetmab (5 mg/mL, 7.5-30 mL; i.v.; 15-30 min) has in vivo efficacy in dogs with naïve T-cell lymphoma (LSA), but resulting in vomiting, weight loss, diarrhoea, lethargy, decreased appetite and anorexia^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>T-cell LSA Model in Dog^[1]</td> </tr> <tr> <td>Dosage:</td> <td>5 mg/mL, 7.5-30 mL; Dogs weighing for 2-15 kg received 7.5 mL, for 15.1-30 kg received 15 mL, for 30.1-45 kg received 22.5 mL, for 45.1-60 kg received 30 mL</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; 15-30 min</td> </tr> <tr> <td>Result:</td> <td>Showed in vivo efficacy with severe side effect.</td> </tr> </table>	Animal Model:	T-cell LSA Model in Dog ^[1]	Dosage:	5 mg/mL, 7.5-30 mL; Dogs weighing for 2-15 kg received 7.5 mL, for 15.1-30 kg received 15 mL, for 30.1-45 kg received 22.5 mL, for 45.1-60 kg received 30 mL	Administration:	Intravenous injection; 15-30 min	Result:	Showed in vivo efficacy with severe side effect.
Animal Model:	T-cell LSA Model in Dog ^[1]								
Dosage:	5 mg/mL, 7.5-30 mL; Dogs weighing for 2-15 kg received 7.5 mL, for 15.1-30 kg received 15 mL, for 30.1-45 kg received 22.5 mL, for 45.1-60 kg received 30 mL								
Administration:	Intravenous injection; 15-30 min								
Result:	Showed in vivo efficacy with severe side effect.								

REFERENCES

- [1]. Musser ML, et al. Randomised trial evaluating chemotherapy alone or chemotherapy and a novel monoclonal antibody for canine T-cell lymphoma: A multicentre US study. *Vet Rec Open*. 2022 Nov 1;9(1):e49.
- [2]. Rhodes L. Changing innovation into a registered product: From concept to regulatory approval. *Theriogenology*. 2018 May;112:75-81.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA